MAGEC2: A Potential Drug Target and Biomarker for Melanoma (G51438)

Target Name: MAGEC2

NCBI ID: G51438

MAGEC2

MAGEC2: A Potential Drug Target and Biomarker for Melanoma

Melanoma is a type of skin cancer that is typically aggressive and has a high mortality rate. It is characterized by the rapid growth of skin cells, which can eventually form a tumor. Melanoma is often treated with chemotherapy, but often develops drug resistance , so researchers are always looking for new treatments and drug targets.

MAGEC2 is a protein that is expressed in skin tissue under normal circumstances. In Melanoma, the expression level of MAGEC2 is significantly increased. MAGEC2 has also been shown to be expressed in many types of cancer, including lung cancer, oral cancer, and kidney cancer.

The expression level of MAGEC2 correlates with the invasiveness and metastasis of Melanoma. Lower MAGEC2 expression levels may mean slower tumor growth, while higher MAGEC2 expression levels may be closely related to tumor invasiveness and metastasis.

MAGEC2 is also associated with tumor aggressiveness and metastasis. Studies have shown that the expression level of MAGEC2 is positively correlated with tumor invasion and metastasis. In addition, the expression level of MAGEC2 is also correlated with the expression levels of proteins related to tumor invasiveness and metastasis.

Therefore, MAGEC2 may be a potential drug target. Researchers are exploring the use of MAGEC2 as a target for therapeutic drugs and studying the relationship between MAGEC2 expression levels in Melanoma and tumor growth and invasiveness. If the study results confirm that MAGEC2 is an effective therapeutic drug target, it may become a new treatment for Melanoma.

MAGEC2 may also be a biomarker. Studies have shown that the expression level of MAGEC2 can be used to predict the survival of Melanoma patients. In addition, the expression level of MAGEC2 can also be used to evaluate the impact of different treatment modalities on the survival of Melanoma patients.

MAGEC2 is an interesting molecule with a potential drug target. The findings suggest that MAGEC2 may be an effective therapeutic drug target and may also be a potential biomarker. Future studies will further investigate the role of MAGEC2 in Melanoma and explore the application of MAGEC2 as a therapeutic drug or biomarker.

Protein Name: MAGE Family Member C2

Functions: Proposed to enhance ubiquitin ligase activity of RING-type zinc finger-containing E3 ubiquitin-protein ligases. In vitro enhances ubiquitin ligase activity of TRIM28 and stimulates p53/TP53 ubiquitination in presence of Ubl-conjugating enzyme UBE2H leading to p53/TP53 degradation. Proposed to act through recruitment and/or stabilization of the Ubl-conjugating enzymes (E2) at the E3:substrate complex

The "MAGEC2 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about MAGEC2 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets